UNICYCIVE THERAPEUTICS, INC. Finance Lease, Principal Payments
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Finance Lease, Principal Payments of $496.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2024-05-13
- UNICYCIVE THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2024-03-31 was $496.00K, a 106.67% increase year-over-year.
- UNICYCIVE THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2023-12-31 was $205.00K.
- UNICYCIVE THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2023-09-30 was $51.00K.
- UNICYCIVE THERAPEUTICS, INC. finance lease, principal payments for the quarter ending 2023-06-30 was $0.00.
- UNICYCIVE THERAPEUTICS, INC. finance lease, principal payments for fiscal 2023 was $496.00K, a 2.90% increase from fiscal 2022.
- UNICYCIVE THERAPEUTICS, INC. finance lease, principal payments for fiscal 2022 was $482.00K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2024-03-31 | $496.00K 10-Q · filed 2024-05-13 | $701.00K derived: sum of 2 quarters · filed 2024-05-13 | $752.00K derived: sum of 3 quarters · filed 2024-05-13 | $752.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $256.00K derived: sum of 2 quarters · filed 2024-03-28 | $256.00K derived: sum of 3 quarters · filed 2024-03-28 | $496.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $51.00K derived: sum of 2 quarters · filed 2023-11-14 | $291.00K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $240.00K 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | $240.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $482.00K 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |